March 16, 2026. 5 cannabis news items, curated from live RSS feeds. Sorted by relevance score.
Does Cannabis Use by Older Adults Accelerate Mental Decline? – Labroots
This article examines whether cannabis use in older adults contributes to cognitive decline and discusses structural variations in synthetic cannabinoid compounds relevant to medical research.
Read more →Study Found CBD and CBG May Counter Fatty Liver Disease | Cannabis Sciences
# Summary A study investigated cannabidiol (CBD) and cannabigerol (CBG) as potential therapeutic agents for treating fatty liver disease, with implications for clinical management of this prevalent liver condition.
Read more →Avicanna Announces Sponsorship Of University Of Calgary Thc Dose Finding Clinical Trial
Avicanna is sponsoring a clinical trial at the University of Calgary to determine optimal THC dosing, advancing evidence-based cannabis research for therapeutic applications.
Read more →With Marijuana Rescheduling Still Pending, Federal Workplace Drug Testing Rules Aren’t …
# Summary This article discusses the status of federal marijuana rescheduling and its implications for workplace drug testing policies, which remain unchanged pending regulatory finalization.
Read more →Breakthrough Laboratory Device Revolutionizes Cannabinoid Extraction and … – Tech Times
# Article Summary A new patented laboratory device improves cannabinoid extraction and analysis using protein spectroscopy technology, advancing analytical methods for cannabinoid research.
Read more →Clinical Commentary
# Clinical Reflection These developments underscore that cannabis medicine is entering a more rigorous evidence phase, with emerging research on CBD and CBG for metabolic disease and controlled THC dosing studies suggesting we’re moving beyond anecdotal practice toward mechanism-based therapeutics, while simultaneously the field faces real-world constraints from federal scheduling uncertainty and workplace policies that create clinical friction regardless of scientific progress. The apparent cognitive safety concerns raised in geriatric populations warrant our careful attention to patient selection and monitoring, particularly as older adults represent a growing proportion of cannabis users seeking treatment for pain and other conditions. Collectively, these signals indicate that responsible cannabis medicine practitioners must balance optimism about cannabinoid pharmacology with intellectual honesty about knowledge gaps and the practical barriers that prevent our patients from accessing evidence-informed care.
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it: